ANDA 208538, held by Gland Pharma. Esmolol Hydrochloride.
As of Nov 21, 2026, ANDA 208538 (Esmolol Hydrochloride), held by Gland Pharma, was first approved by FDA on Aug 14, 2019, with 1 approved supplement and 0 published complete response letters.
Esmolol hydrochloride injection is a beta adrenergic blocker indicated for the short-term treatment of: Control of ventricular rate in supraventricular tachycardia including atrial fibrillation and atrial flutter and control of heart rate in noncompensatory sinus tachycardia Control of perioperative tachycardia and hypertension 1.1 Supraventricular Tachycardia or Noncompensatory Sinus Tachycardia Esmolol hydrochloride injection is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 14, 2019 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Esmolol Hydrochloride10MG/ML · injectable;injection | Esmolol Hydrochloride | Rx |
| Aug 10, 2023 | Supplement 2Labeling · Standard review | Approved | None posted |
| Aug 14, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters